Constellation Pharmaceuticals Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Constellation Pharmaceuticals stock.
View analyst ratings for Constellation Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Constellation Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its earnings results on Thursday, October, 29th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.03.
View Constellation Pharmaceuticals' earnings history.

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CNST stock has decreased by 16.3% and is now trading at $27.26.
View which stocks have been most impacted by COVID-19.

8 brokers have issued 12-month price targets for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $75.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $46.00 in the next year. This suggests a possible upside of 68.7% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Constellation Pharmaceuticals include GW Pharmaceuticals (GWPH), Evotec (EVTCY), Sarepta Therapeutics (SRPT), Atea Pharmaceuticals (AVIR), Allakos (ALLK), TG Therapeutics (TGTX), Perrigo (PRGO), Turning Point Therapeutics (TPTX), Blueprint Medicines (BPMC), Galapagos (GLPG), Maravai LifeSciences (MRVI), Emergent BioSolutions (EBS), Biohaven Pharmaceutical (BHVN), Eidos Therapeutics (EIDX) and FibroGen (FGEN).
View all of CNST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (6.20%), BlackRock Inc. (5.46%), Lord Abbett & CO. LLC (3.54%), Morgan Stanley (2.58%), Jennison Associates LLC (2.49%) and Victory Capital Management Inc. (2.47%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, PFM Health Sciences LP, Regents of The University of California, Price T Rowe Associates Inc. MD, Ghost Tree Capital LLC, SG Americas Securities LLC, P.A.W. Capital Corp, and Credit Suisse AG. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, and Patrick Trojer.
View insider buying and selling activity for Constellation Pharmaceuticals or view top insider-selling stocks.

CNST stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Lord Abbett & CO. LLC, BlackRock Inc., Jennison Associates LLC, Victory Capital Management Inc., GSA Capital Partners LLP, Alliancebernstein L.P., and Silverarc Capital Management LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals or or view top insider-buying stocks.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNST stock can currently be purchased for approximately $27.26.

Constellation Pharmaceuticals has a market capitalization of $1.30 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

Constellation Pharmaceuticals employs 106 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]